These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 20532645)

  • 21. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
    de Jong N; Kester AD; Schouten HC; Abu-Saad HH; Courtens AM
    Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
    Ruffert K
    Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
    Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
    Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemotherapy of disseminated forms of breast cancer using platinum derivatives].
    Gorbunova VA; Trofimova NB; Manziuk LV
    Vopr Onkol; 1990; 36(4):455-7. PubMed ID: 2345995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
    Cameron DA; Gregory WM; Bowman A; Anderson ED; Levack P; Forouhi P; Leonard RC
    Br J Cancer; 2000 Jul; 83(1):98-103. PubMed ID: 10883676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
    Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
    J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
    Vogel CL; Raney M; Carpenter J
    Cancer Treat Rep; 1987 Dec; 71(12):1271-3. PubMed ID: 3690536
    [No Abstract]   [Full Text] [Related]  

  • 34. Doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
    Michaelsoln RA
    JAMA; 1995 Sep; 274(10):796-7. PubMed ID: 7650797
    [No Abstract]   [Full Text] [Related]  

  • 35. Optimal control for a stochastic model of cancer chemotherapy.
    Coldman AJ; Murray JM
    Math Biosci; 2000 Dec; 168(2):187-200. PubMed ID: 11121565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour dormancy in breast cancer: an update.
    Brackstone M; Townson JL; Chambers AF
    Breast Cancer Res; 2007; 9(3):208. PubMed ID: 17561992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone.
    Orzechowska-Juzwenko K; Wiela A; Cieślińska A; Roszkowska E
    Cancer; 1987 May; 59(9):1607-10. PubMed ID: 3828961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computer model challenges breast cancer treatment strategy.
    Retsky MW; Swartzendruber DE; Bame PD; Wardwell RH
    Cancer Invest; 1994; 12(6):559-67. PubMed ID: 7994590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling of Mouse Experiments Suggests that Optimal Anti-Hormonal Treatment for Breast Cancer is Diet-Dependent.
    Akman T; Arendt LM; Geisler J; Kristensen VN; Frigessi A; Köhn-Luque A
    Bull Math Biol; 2024 Mar; 86(4):42. PubMed ID: 38498130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration.
    Mohammad Mirzaei N; Su S; Sofia D; Hegarty M; Abdel-Rahman MH; Asadpoure A; Cebulla CM; Chang YH; Hao W; Jackson PR; Lee AV; Stover DG; Tatarova Z; Zervantonakis IK; Shahriyari L
    J Pers Med; 2021 Oct; 11(10):. PubMed ID: 34683171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.